234 related articles for article (PubMed ID: 36615391)
1. Acridine as an Anti-Tumour Agent: A Critical Review.
Varakumar P; Rajagopal K; Aparna B; Raman K; Byran G; Gonçalves Lima CM; Rashid S; Nafady MH; Emran TB; Wybraniec S
Molecules; 2022 Dec; 28(1):. PubMed ID: 36615391
[TBL] [Abstract][Full Text] [Related]
2. A Review on Acridines as Antiproliferative Agents.
Baliwada A; Rajagopal K; Varakumar P; Raman K; Byran G
Mini Rev Med Chem; 2022; 22(21):2769-2798. PubMed ID: 35546777
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of benzimidazole acridine derivatives as potential DNA-binding and apoptosis-inducing agents.
Gao C; Li B; Zhang B; Sun Q; Li L; Li X; Chen C; Tan C; Liu H; Jiang Y
Bioorg Med Chem; 2015 Apr; 23(8):1800-7. PubMed ID: 25778766
[TBL] [Abstract][Full Text] [Related]
4. New Acridine Thiourea Gold(I) Anticancer Agents: Targeting the Nucleus and Inhibiting Vasculogenic Mimicry.
Pérez SA; de Haro C; Vicente C; Donaire A; Zamora A; Zajac J; Kostrhunova H; Brabec V; Bautista D; Ruiz J
ACS Chem Biol; 2017 Jun; 12(6):1524-1537. PubMed ID: 28388047
[TBL] [Abstract][Full Text] [Related]
5. Redesigning the DNA-targeted chromophore in platinum-acridine anticancer agents: a structure-activity relationship study.
Pickard AJ; Liu F; Bartenstein TF; Haines LG; Levine KE; Kucera GL; Bierbach U
Chemistry; 2014 Dec; 20(49):16174-87. PubMed ID: 25302716
[TBL] [Abstract][Full Text] [Related]
6. Acridine derivatives as chemotherapeutic agents.
Denny WA
Curr Med Chem; 2002 Sep; 9(18):1655-65. PubMed ID: 12171548
[TBL] [Abstract][Full Text] [Related]
7. Replacement of a thiourea with an amidine group in a monofunctional platinum-acridine antitumor agent. Effect on DNA interactions, DNA adduct recognition and repair.
Kostrhunova H; Malina J; Pickard AJ; Stepankova J; Vojtiskova M; Kasparkova J; Muchova T; Rohlfing ML; Bierbach U; Brabec V
Mol Pharm; 2011 Oct; 8(5):1941-54. PubMed ID: 21806015
[TBL] [Abstract][Full Text] [Related]
8. Novel tetra-acridine derivatives as dual inhibitors of topoisomerase II and the human proteasome.
Vispé S; Vandenberghe I; Robin M; Annereau JP; Créancier L; Pique V; Galy JP; Kruczynski A; Barret JM; Bailly C
Biochem Pharmacol; 2007 Jun; 73(12):1863-72. PubMed ID: 17391647
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of action of DNA intercalating acridine-based drugs: how important are contributions from electron transfer and oxidative stress?
Baguley BC; Wakelin LP; Jacintho JD; Kovacic P
Curr Med Chem; 2003 Dec; 10(24):2643-9. PubMed ID: 14529454
[TBL] [Abstract][Full Text] [Related]
10. CK0403, a 9‑aminoacridine, is a potent anti‑cancer agent in human breast cancer cells.
Sun YW; Chen KY; Kwon CH; Chen KM
Mol Med Rep; 2016 Jan; 13(1):933-8. PubMed ID: 26648164
[TBL] [Abstract][Full Text] [Related]
11. Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II.
Oppegard LM; Ougolkov AV; Luchini DN; Schoon RA; Goodell JR; Kaur H; Billadeau DD; Ferguson DM; Hiasa H
Eur J Pharmacol; 2009 Jan; 602(2-3):223-9. PubMed ID: 19071108
[TBL] [Abstract][Full Text] [Related]
12. Design of a platinum-acridine-endoxifen conjugate targeted at hormone-dependent breast cancer.
Ding S; Qiao X; Kucera GL; Bierbach U
Chem Commun (Camb); 2013 Mar; 49(24):2415-7. PubMed ID: 23416453
[TBL] [Abstract][Full Text] [Related]
13. Influence of polyamine architecture on the transport and topoisomerase II inhibitory properties of polyamine DNA-intercalator conjugates.
Wang L; Price HL; Juusola J; Kline M; Phanstiel O
J Med Chem; 2001 Oct; 44(22):3682-91. PubMed ID: 11606133
[TBL] [Abstract][Full Text] [Related]
14. Expedient synthesis and anticancer evaluation of dual-action 9-anilinoacridine methyl triazene chimeras.
Walunj D; Egarmina K; Tuchinsky H; Shpilberg O; Hershkovitz-Rokah O; Grynszpan F; Gellerman G
Chem Biol Drug Des; 2021 Feb; 97(2):237-252. PubMed ID: 32772433
[TBL] [Abstract][Full Text] [Related]
15. From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.
Finlay GJ; Riou JF; Baguley BC
Eur J Cancer; 1996 Apr; 32A(4):708-14. PubMed ID: 8695277
[TBL] [Abstract][Full Text] [Related]
16. 5,7-Disubstituted analogues of the mixed topoisomerase I/II poison N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA): DNA binding and patterns of cytotoxicity.
Spicer JA; Finlay GJ; Baguley BC; Velea L; Graves DE; Denny WA
Anticancer Drug Des; 1999 Feb; 14(1):37-45. PubMed ID: 10363026
[TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships for substituted bis(acridine-4-carboxamides): a new class of anticancer agents.
Gamage SA; Spicer JA; Atwell GJ; Finlay GJ; Baguley BC; Denny WA
J Med Chem; 1999 Jul; 42(13):2383-93. PubMed ID: 10395479
[TBL] [Abstract][Full Text] [Related]
18. Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines.
Othman S; Kozurkova M
Curr Med Chem; 2018; 25(17):1968-1975. PubMed ID: 28413957
[TBL] [Abstract][Full Text] [Related]
19. 2,6-Di(omega-aminoalkyl)-2,5,6,7-tetrahydropyrazolo[3,4,5-mn]pyrimido[5,6,1-de]acridine-5,7-diones: novel, potent, cytotoxic, and DNA-binding agents.
Antonini I; Polucci P; Magnano A; Gatto B; Palumbo M; Menta E; Pescalli N; Martelli S
J Med Chem; 2002 Jan; 45(3):696-702. PubMed ID: 11806721
[TBL] [Abstract][Full Text] [Related]
20. [The structural and functional analysis of the biological activity of acridine derivatives].
Deeva EG; Pavlovskaia IaV; Kiselev OI; Kiselev VI; Piotrovskiĭ LB; Ershov FI
Vestn Ross Akad Med Nauk; 2004; (2):29-34. PubMed ID: 15101206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
